Deep Dive: Deep Dive Into Activity in the Alzheimer's Pipeline

After a year of controversy and conversation in Alzheimer disease that saw the first approval for the field in 2 decades, Dr. Anton Porsteinsson shared his perspective on the progress made and commented on the agents moving through the pipeline and the state of things heading into 2022.